about
Survival benefit from S-1 as compared to Fluorouracil in Asian patients with advanced gastrointestinal cancer: a meta-analysis.Anaplastic lymphoma kinase aberrations correlate with metastatic features in pediatric rhabdomyosarcoma.S-1 as a core anticancer fluoropyrimidine agent.The High Prevalence of Functional Complement Defects Induced by Chemotherapy.New approaches for pediatric rhabdomyosarcoma drug discovery: targeting combinatorial signaling.Using a rhabdomyosarcoma patient-derived xenograft to examine precision medicine approaches and model acquired resistance.
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacotherapy for pediatric soft-tissue sarcomas.
@en
Pharmacotherapy for pediatric soft-tissue sarcomas.
@nl
type
label
Pharmacotherapy for pediatric soft-tissue sarcomas.
@en
Pharmacotherapy for pediatric soft-tissue sarcomas.
@nl
prefLabel
Pharmacotherapy for pediatric soft-tissue sarcomas.
@en
Pharmacotherapy for pediatric soft-tissue sarcomas.
@nl
P2860
P1476
Pharmacotherapy for pediatric soft-tissue sarcomas.
@en
P2860
P304
P356
10.1517/14656566.2011.524926
P407
P577
2011-03-01T00:00:00Z